借助处方前置审核系统实施含β-内酰胺酶抑制剂复合制剂精细化管理  

Fine Management of β-lactamase Inhibitor Compound Preparations Through the Pre-prescription Review System

作　　者：李静[1] 宋惠珠[1] 周晓[1] 虞琳 马红燕[1] LI Jing;SONG Huizhu;ZHOU Xiao;YU Lin;MA Hongyan(Department of Pharmacy,the Affiliated Wuxi People's Hospital of Nanjing Medical University,Wuxi 214023,China)

机构地区：[1]南京医科大学附属无锡市人民医院药剂科,无锡214023

出　　处：《医药导报》2020年第9期1230-1233,共4页Herald of Medicine

基　　金：江苏省药学会奥赛康医院药学科研项目(A201917)。

摘　　要：目的促进含β-内酰胺酶抑制剂复合制剂(简称“含酶抑制剂复合制剂”)的处方前置审核及临床合理使用。方法借助处方前置审核系统(MIND系统)开发自维护规则库,对含酶抑制剂复合制剂的处方权限、病原学送检、用法用量、联合用药、疗程等进行精细化设置;统计管理前后药品的使用率、会诊率、疗程,以及抽样点评中医嘱合格率,评价精细化设置的效果。结果精细化管理后,含酶抑制剂复合制剂使用率由8.25%降至5.82%,会诊率由11.43%提高至77.40%,平均疗程缩短,抽样点评医嘱不合格率由38.33%降至4.76%,适应证、用法用量、联合用药及疗程不适宜等问题均显著改善。结论对含酶抑制剂复合制剂的信息化精细设置可促进前置审方工作的开展,促进药品的合理使用。Objective To promote the pre-prescription review and proper clinical use ofβ-lactamase inhibitor compound preparations.Methods A“self-maintenance rule base”was established with the help of the pre-prescription review system(MIND system),and fine set the prescription authority,etiology inspection,usage and dosage,combined medication,treatment course,etc.of theβ-lactamase inhibitor compound preparation.The utilization rate,consultation rate,course of treatment of the drugs before and after the management were calculated,the qualified rate of prescriptions was evaluated by sampling,and the effect of fine setting was evaluated.Results After fine management,the utilization rate ofβ-lactamase inhibitor compound preparation in the hospital decreased from 8.25%to 5.82%,the consultation rate increased from 11.43%to 77.40%.The average therapy duration was shortened,and the unqualified rate of prescriptions decreased from 38.33%to 4.76%.The problems such as indications,usage and dosage,combined medication and course of treatment were significantly improved.Conclusion The fine setting of the rules forβ-lactamase inhibitor compound preparation could effectively promote the development of pre-prescription review and promote the rational use of drugs.

关 键 词：处方前置审核 含β-内酰胺酶抑制剂复合制剂 用药规则 精细化管理 合理用药 

分 类 号：R951[医药卫生—药学] R969.3